Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 853-859

  Hirata, Yuji ^a   Yokote, Taiji ^a   Kobayashi, Kichinosuke ^a   Nakayama, Shoko ^a   Oka, Satoko ^a   Miyoshi, Takuji ^a   Akioka, Toshikazu ^a   Hiraoka, Nobuya ^a   Iwaki, Kazuki ^a   Takayama, Ayami ^a   Nishimura, Yasuichiro ^a   Makino, Junko ^a   Takubo, Takayuki ^a   Tsuji, Motomu ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

1,3 d glucan; Antifungal prophylaxis; Invasive fungal infection; Micafungin

Indexed keywords

ENDO 1,3 BETA GLUCANASE; GRANULOCYTE COLONY STIMULATING FACTOR; MICAFUNGIN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMIC MYCOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-GLUCANS; ECHINOCANDINS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; LIPOPEPTIDES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; YOUNG ADULT;

EID: 77951812068     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003682726     Document Type: Article

References (35)

1. Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
2. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nübling G, Hübner K. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
3. Rüchel R. Diagnosis of invasive mycoses in severely immunosuppressed patients. Ann Hematol 1993;67:1-11.
4. Denning DW, Evans EG, Kibbler CC, et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Clin Microbiol Infect Dis 1997;16:424-436.
5. Viscoli C, Castagnola E, Machetti M. Antifungal treatment in patients with cancer. J Intern Med 1997; 242 (Suppl. 740) : 89-94.
6. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-284.
7. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56: i23-i32.
8. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2008;356:348-359.
9. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990;161:397-401.
10. Senn L, Robinson JO, Schmidt S, et al. BG antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008;46:878-885.
11. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
12. Cometta A, Kern WV, De BR, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382-389.
13. Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000;18:3690-3698.
14. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004;42:2733-2741.
15. Bow EJ. Invasive fungal infection in patients receiving intensive cytotoxic therapy for cancer. Br J Haematol 1998;101:1-4.
16. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-369.
17. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-740.
18. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and metaanalysis. J Clin Oncol 2007;25:5471-5489.
19. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
20. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-1041.
21. Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901-911.
22. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell'Adulto. Clin Infect Dis 1999;28:250-255.
23. Vehreschild J, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445-449.
24. Mujisers RBR, Goa KL, Scott LJ, et al. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002;62:2655-2664.
25. Tollemar J, Ringden O, Andersson S, et al. Randomized double blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-582.
26. Tollemar J, Ringden O, Andersson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25:1495-1497.
27. Tollemar J, Hockerstedt K, Ericzon BG, et al. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994;26:1833.
28. Maertens J. Evaluating prophylaxis of invasive fungal infection in patients with haematologic malignancies. Eur J Haematol 2007;78:275-278.
29. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-1178.
30. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49:1331-1336.
31. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002;48:78-81.
32. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;47:57-62.
33. van Burik JH, Ratanatharathorn V, Stephan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-1416.
34. Hashino S, Morita L, Takahata M, et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008;87:91-97.
35. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007;27:1644-1650.